<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "9: single source", fill: "#f4f0ec"},
{source: "9: single source", target: "9: ultrasonic aspirator", fill: "#f4f0ec"},
{source: "9: ultrasonic aspirator", target: "9: United States ", fill: "#f4f0ec"},
{source: "9: United States ", target: "9: internationally", fill: "#f4f0ec"},
{source: "9: internationally", target: "9: Synergetics Omni ", fill: "#f4f0ec"},
{source: "9: single source", target: "11: manufacture", fill: "#d73b3e"},
{source: "11: manufacture", target: "11: xenon light source depends on single sources", fill: "#d73b3e"},
{source: "11: xenon light source depends on single sources", target: "11: several key", fill: "#d73b3e"},
{source: "11: several key", target: "11: components", fill: "#d73b3e"},
{source: "11: manufacture", target: "16: also become aware", fill: "#fc89ac"},
{source: "16: also become aware", target: "16: manufacturers", fill: "#fc89ac"},
{source: "16: manufacturers", target: "16: several parts used", fill: "#fc89ac"},
{source: "16: several parts used", target: "16: manufacturing", fill: "#fc89ac"},
{source: "16: also become aware", target: "19: Alternative ", fill: "#708090"},
{source: "19: Alternative ", target: "19: available will", fill: "#708090"},
{source: "19: available will", target: "19: engineering redesign", fill: "#708090"},
{source: "19: engineering redesign", target: "19: regulatory approval", fill: "#708090"},
{source: "19: regulatory approval", target: "19: manufacture", fill: "#708090"},
{source: "19: manufacture", target: "19: additional new units", fill: "#708090"},
{source: "19: Alternative ", target: "21: technology", fill: "#8fbc8f"},
{source: "21: technology", target: "21: characterized", fill: "#8fbc8f"},
{source: "21: characterized", target: "21: competition", fill: "#8fbc8f"},
{source: "21: technology", target: "23: competitors", fill: "#fdd5b1"},
{source: "23: competitors", target: "23: development", fill: "#fdd5b1"},
{source: "23: development", target: "23: manufacturing", fill: "#fdd5b1"},
{source: "23: manufacturing", target: "23: distribution", fill: "#fdd5b1"},
{source: "23: distribution", target: "23: resources than", fill: "#fdd5b1"},
{source: "23: competitors", target: "24: Furthermore ", fill: "#df00ff"},
{source: "24: Furthermore ", target: "24: competitors may", fill: "#df00ff"},
{source: "24: competitors may", target: "24: effective at implementing", fill: "#df00ff"},
{source: "24: effective at implementing", target: "24: technologies", fill: "#df00ff"},
{source: "24: technologies", target: "24: commercial products", fill: "#df00ff"},
{source: "24: Furthermore ", target: "27: competitive position depends on", fill: "#ccf"},
{source: "27: competitive position depends on", target: "27: acceptance", fill: "#ccf"},
{source: "27: acceptance", target: "27: new products", fill: "#ccf"},
{source: "27: new products", target: "27: secure regulatory approval", fill: "#ccf"},
{source: "27: secure regulatory approval", target: "27: products under development", fill: "#ccf"},
{source: "27: products under development", target: "27: intellectual", fill: "#ccf"},
{source: "27: competitive position depends on", target: "28: applications", fill: "#0000cd"},
{source: "28: applications", target: "28: remain competitive", fill: "#0000cd"},
{source: "28: applications", target: "37: medical community will accept", fill: "#ffb6c1"},
{source: "37: medical community will accept", target: "37: new multifunctional", fill: "#ffb6c1"},
{source: "37: new multifunctional", target: "37: electrosurgical", fill: "#ffb6c1"},
{source: "37: electrosurgical", target: "37: generator", fill: "#ffb6c1"},
{source: "37: generator", target: "37: proprietary", fill: "#ffb6c1"},
{source: "37: proprietary", target: "37: instruments", fill: "#ffb6c1"},
{source: "37: instruments", target: "37: existing bipolar", fill: "#ffb6c1"},
{source: "37: existing bipolar", target: "37: electrosurgical generators", fill: "#ffb6c1"},
{source: "37: medical community will accept", target: "START_HERE", fill: "#ffb6c1"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/History_of_the_United_States">History of the United States</a></td>
      <td>The history of the lands that became the United States began with the arrival of the first people in the Americas around 15,000 BC. Numerous indigenous cultures formed, and many saw transformations in the 16th century away from more densely populated lifestyles and towards reorganized polities elsewhere.  The European colonization of the Americas began in the late 15th century, however most colonies in what would later become the United States were settled after 1600.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Democratic_Party_(United_States)">Democratic Party (United States)</a></td>
      <td>The Democratic Party is one of the two major contemporary political parties in the United States. It was founded in 1828 by supporters of Andrew Jackson, making it the world's oldest active political party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_cost">Manufacturing cost</a></td>
      <td>Manufacturing cost is the sum of costs of all resources consumed in the process of making a product. The manufacturing cost is classified into three categories: direct materials cost, direct labor cost and manufacturing overhead.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Praziquantel">Praziquantel</a></td>
      <td>Praziquantel (PZQ), sold under the brandname Biltricide among others, is a medication used to treat a number of types of parasitic worm infections in mammals, birds, amphibians, reptiles, and fish. In humans specifically, it is used to treat schistosomiasis, clonorchiasis, opisthorchiasis, tapeworm infections, cysticercosis, hydatid disease, and other fluke infections.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tecovirimat">Tecovirimat</a></td>
      <td>Tecovirimat, sold under the brand name Tpoxx among others, is an antiviral medication with activity against orthopoxviruses such as smallpox and monkeypox. It is the first antipoxviral drug approved in the United States.The drug works by blocking cellular transmission of the virus, thus preventing the disease.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Food_and_Drug_Administration">Food and Drug Administration</a></td>
      <td>The United States Food and Drug Administration (FDA or USFDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods &amp; feed and veterinary products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Denosumab">Denosumab</a></td>
      <td>Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is contraindicated in people with low blood calcium levels. The most common side effects are joint and muscle pain in the arms or legs.Denosumab is a inhibitor of RANKL (receptor activator of nuclear factor kappa-Β ligand), which works by preventing the development of osteoclasts, which are cells that break down bone.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_product_development">New product development</a></td>
      <td>In business and engineering, new product development (NPD) covers the complete process of bringing a new product to market, renewing an existing product or introducing a product in a new market. A central aspect of NPD is product design, along with various business considerations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Timeline_of_Apple_Inc._products">Timeline of Apple Inc. products</a></td>
      <td>This timeline of Apple Inc. products is a list of all stand-alone Apple II, Macintosh, and other computers, as well as computer peripherals, expansion cards, ancillary products, and consumer electronics sold by Apple Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_design">Product design</a></td>
      <td>Product design as a verb is to create a new product to be sold by a business to its customers. A very broad coefficient and effective generation and development of ideas through a process that leads to new products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_innovation">Product innovation</a></td>
      <td>Product innovation is the creation and subsequent introduction of a good or service that is either new, or an improved version of previous goods or services. This is broader than the normally accepted definition of innovation that includes the invention of new products which, in this context, are still considered innovative.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Godrej_Consumer_Products">Godrej Consumer Products</a></td>
      <td>Godrej Consumer Products Limited (GCPL) is an Indian consumer goods company based in Mumbai, India. GCPL's products include soap, hair colourants, toiletries and liquid detergents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_strategy">Product strategy</a></td>
      <td>Product strategy defines the high-level plan for developing and marketing a product, how the product supports the business strategy and goals, and is brought to life through product roadmaps. A product strategy describes a vision of the future with this product, the ideal customer profile and market to serve, go-to-market and positioning (marketing), thematic areas of investment, and measures of success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Application_software">Application software</a></td>
      <td>An application program (application or app for short) is a computer program designed to carry out a specific task other than one relating to the operation of the computer itself, typically to be used by end-users. Word processors, media players, and accounting software are examples of.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mobile_app">Mobile app</a></td>
      <td>A mobile application or app is a computer program or software application designed to run on a mobile device such as a phone, tablet, or watch. Mobile applications often stand in contrast to desktop applications which are designed to run on desktop computers, and web applications which run in mobile web browsers rather than directly on the mobile device.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_protocol">Proprietary protocol</a></td>
      <td>In telecommunications, a proprietary protocol is a communications protocol owned by a single organization or individual.\n\n\n== Intellectual property rights and enforcement ==\nOwnership by a single organization gives the owner the ability to place restrictions on the use of the protocol and to change the protocol unilaterally.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SYNERGETICS USA INC      Item 1A Risk Factors          In addition to the other information contained in this Form 10-K, we     have  identified the <font color="blue">following risks</font> and <font color="blue">uncertainties</font> that may have a     material adverse effect on our business, <font color="blue">financial condition</font> or results of     operation</td>
    </tr>
    <tr>
      <td>You <font color="blue">should carefully</font> consider the <font color="blue">risks described</font> below before     making an <font color="blue"><font color="blue">investment</font> decision</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> part of our sales of our <font color="blue">neurosurgical products comes from</font> a     single customer, which makes us vulnerable to the loss of that customer</td>
    </tr>
    <tr>
      <td>Codman <font color="blue">currently accounts</font> for most of our <font color="blue"><font color="blue">total revenue</font> from sales</font> of     our  bipolar  <font color="blue"><font color="blue"><font color="blue">electrosurgical</font> <font color="blue">generator</font></font>s</font></td>
    </tr>
    <tr>
      <td>During the fiscal year ended     July 2006, revenue from sales of our bipolar <font color="blue"><font color="blue"><font color="blue">electrosurgical</font> <font color="blue">generator</font></font>s</font>     represented approximately 17prca of the Company’s <font color="blue">total revenue</font></td>
    </tr>
    <tr>
      <td>Under our     <font color="blue">existing <font color="blue">agreement with</font></font> Codman, Codman <font color="blue">distributes</font> the <font color="blue">third generation</font>     <font color="blue"><font color="blue">generator</font> trademarked as</font> the CMCIII on an <font color="blue">exclusive basis</font></td>
    </tr>
    <tr>
      <td>Our existing     <font color="blue">agreement with</font> Codman will expire by its own terms on <font color="blue">December </font>31, 2008,     <font color="blue">unless extended by mutual agreement</font> of the parties</td>
    </tr>
    <tr>
      <td>_________________________________________________________________           If any of our <font color="blue"><font color="blue">single source</font> suppliers</font> were to <font color="blue">cease providing <font color="blue">components</font></font>, we     may not be able to produce our products</td>
    </tr>
    <tr>
      <td>We rely on a <font color="blue">single source</font> for the supply of the <font color="blue">ultrasonic aspirator</font>     sold in the <font color="blue">United States </font>and <font color="blue">internationally</font> under Synergetics’ Omni^^®     brand</td>
    </tr>
    <tr>
      <td>Net sales of Synergetics’ Omni^® <font color="blue">ultrasonic aspirator</font>s for each of     our <font color="blue">fiscal years</font> ended July 31, 2006 and 2005 amounted to greater than 10prca     of <font color="blue">total net sales</font> for <font color="blue">each period</font></td>
    </tr>
    <tr>
      <td>Also, the <font color="blue">manufacture</font> of Synergetics’     Photon^TM xenon light source depends on <font color="blue">single source</font>s for <font color="blue">several key</font>     <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>In  addition,  we  <font color="blue">subcontract</font> for the <font color="blue">manufacture</font> of the     <font color="blue">disposable cord</font> and <font color="blue">tubing sets</font> for the Malis^® <font color="blue"><font color="blue">electrosurgical</font> <font color="blue">generator</font></font>     with a single <font color="blue">manufacture</font>r</td>
    </tr>
    <tr>
      <td>If any of these <font color="blue">suppliers become unwilling</font> or     unable to <font color="blue">provide products</font> or <font color="blue">components</font> in the required volumes and quality     levels or in a <font color="blue">timely manner</font>, we would be required to locate and contract     <font color="blue">with <font color="blue">substitute supplier</font>s</font></td>
    </tr>
    <tr>
      <td>Although we believe that <font color="blue">alternative sources</font> for     many of these <font color="blue">components</font> and <font color="blue">raw materials</font> are available, we could have     <font color="blue"><font color="blue">difficult</font>y</font>  identifying a <font color="blue">substitute supplier</font> in a <font color="blue">timely manner</font> or on     <font color="blue"><font color="blue">commercially</font> reasonable terms</font> and may have to <font color="blue">pay higher prices</font> to obtain     the <font color="blue"><font color="blue">necessary</font> materials</font></td>
    </tr>
    <tr>
      <td>Any supply interruption could harm our ability to     <font color="blue">manufacture</font> our <font color="blue">products until</font> a new source of supply is identified and     qualified</td>
    </tr>
    <tr>
      <td>We have <font color="blue">also become aware</font> that the <font color="blue">manufacture</font>rs of <font color="blue">several parts used</font>     in our <font color="blue">third generation</font> bipolar <font color="blue"><font color="blue">electrosurgical</font> <font color="blue">generator</font></font> models will no     longer  be <font color="blue">manufacturing</font> these parts in the near future</td>
    </tr>
    <tr>
      <td>While we have     arranged to purchase and maintain a <font color="blue">significant</font> inventory of these parts,     our <font color="blue">efforts may</font> not be <font color="blue">sufficient depending on</font> our unit sales</td>
    </tr>
    <tr>
      <td>We must     develop <font color="blue">alternative sources</font> for these <font color="blue">parts as well as alternative parts</font></td>
    </tr>
    <tr>
      <td><font color="blue">Alternative </font>parts, if available, will require <font color="blue"><font color="blue">engineering</font> redesign</font> and may     require <font color="blue"><font color="blue">regulatory</font> approval</font> before the <font color="blue">manufacture</font> of <font color="blue"><font color="blue">additional</font> new units</font></td>
    </tr>
    <tr>
      <td>The medical device industry is <font color="blue">highly <font color="blue">competitive</font></font>, and we may be unable to     <font color="blue">compete <font color="blue">effectively</font> with</font> other companies</td>
    </tr>
    <tr>
      <td>The  medical  <font color="blue">technology</font>  industry  is  <font color="blue">characterized</font>  by intense     <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>We compete with established medical <font color="blue">technology</font> companies and     <font color="blue">early stage companies</font> that have <font color="blue">alternative solutions</font> for the markets we     serve or intend to serve</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have access to greater     financial, technical, research and <font color="blue">development</font>, marketing, <font color="blue">manufacturing</font>,     sales, <font color="blue">distribution</font> services and other <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>Furthermore,     our <font color="blue">competitors</font> may be more <font color="blue">effective at implementing</font> their <font color="blue">technologies</font> to     develop <font color="blue">commercial products</font></td>
    </tr>
    <tr>
      <td>Certain of the <font color="blue">medical <font color="blue">indications</font></font> that can be     <font color="blue">treated by</font> our devices can also be <font color="blue">treated by</font> other <font color="blue">medical devices</font> or by     <font color="blue">medical practices</font> that do not include a device</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">medical community</font> widely</font>     accepts many <font color="blue">alternative <font color="blue">treatments</font></font> and certain of these other <font color="blue">treatments</font>     have a <font color="blue">long history</font> of use</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue"><font color="blue">competitive</font> position depends</font> on</font> our ability to achieve market     <font color="blue">acceptance</font> for our products, develop <font color="blue">new products</font>, implement production and     marketing plans, secure <font color="blue"><font color="blue">regulatory</font> approval</font> for products under <font color="blue">development</font>     and  protect  our  <font color="blue">intellectual</font>  property</td>
    </tr>
    <tr>
      <td>We may need to develop new     <font color="blue"><font color="blue">application</font>s</font> for our products to <font color="blue">remain <font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Technological </font>advances     by one or more of our current or future <font color="blue">competitors</font> could render our present     or <font color="blue"><font color="blue">future products</font> obsolete</font> or uneconomical</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">future success</font> depends upon</font>     our ability to compete <font color="blue">effectively</font> against current <font color="blue">technology</font> as well as     respond  <font color="blue">effectively</font> to <font color="blue">technological advances</font> and upon our ability to     <font color="blue">successfully</font> implement our <font color="blue">marketing strategies</font> and execute our research and     <font color="blue">development</font> plan</td>
    </tr>
    <tr>
      <td>Our future results are <font color="blue">dependent</font>, in part, upon the <font color="blue">successful <font color="blue">introduction</font></font>     of our fourth generation <font color="blue">multifunctional</font> bipolar <font color="blue"><font color="blue">electrosurgical</font> <font color="blue">generator</font></font>,     <font color="blue">marketed as</font> the Malis^^® Advantage^TM          Our <font color="blue">future success</font>, in part, is <font color="blue">dependent</font> upon the <font color="blue">successful launch</font> of     our  new  <font color="blue">multifunctional</font>  bipolar  <font color="blue">electrosurgical</font>  <font color="blue">generator</font> and new     <font color="blue">proprietary</font> single-use, hand-switching bipolar <font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>We announced     these  products  on  October 8,  2005  at  the 56th <font color="blue">Annual Congress </font>of     <font color="blue">Neurosurgeons Meeting</font></td>
    </tr>
    <tr>
      <td>Their success in the marketplace is <font color="blue">dependent</font> upon     <font color="blue">several factors</font> including:         _________________________________________________________________             •   their <font color="blue">acceptance</font> by surgeons;         •   the <font color="blue">recognition</font> of hospitals and <font color="blue">surgical centers</font> that the new     <font color="blue">generator</font> and <font color="blue"><font color="blue">instruments</font> offer sufficient <font color="blue">advantages</font></font> and benefits to     warrant the cost of purchasing the Malis^® Advantage^TM;         •   our ability to create an <font color="blue">effective sales network</font>;         •   our ability to sustain our <font color="blue">average selling price through</font> this network;     and         •   the reaction of our <font color="blue">competitors</font> in this market</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products may</font> not be accepted in the market</td>
    </tr>
    <tr>
      <td>We cannot be certain that our <font color="blue">current products</font> or any other products we     may develop or <font color="blue">market will</font> achieve or maintain market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>We cannot     be certain that our devices and the procedures they perform will be able to     replace  those established <font color="blue">treatments</font> or that <font color="blue">either physicians</font> or the     <font color="blue">medical community</font> in <font color="blue">general will accept</font> and utilize our devices or any     other  <font color="blue">medical products</font> that we may develop</td>
    </tr>
    <tr>
      <td>For example, we cannot be     certain that the <font color="blue">medical community</font> will accept our new <font color="blue">multifunctional</font>     <font color="blue">electrosurgical</font>   <font color="blue">generator</font>  and  <font color="blue">proprietary</font>  hand-switching  bipolar     <font color="blue">electrosurgical</font> <font color="blue">instruments</font> over traditional monopolar and <font color="blue">existing bipolar</font>     <font color="blue"><font color="blue"><font color="blue">electrosurgical</font> <font color="blue">generator</font></font>s</font> and <font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>Market <font color="blue">acceptance</font> of our <font color="blue">products depends on</font> many factors, including     our ability to:       •   convince third-party <font color="blue">distributors</font> and customers that our <font color="blue">technology</font> is     an <font color="blue">attractive alternative</font> to other <font color="blue">technologies</font>;         •   <font color="blue">manufacture</font> products in <font color="blue">sufficient quantities</font> and at acceptable costs;     and         •   supply and service <font color="blue">sufficient quantities</font> of our <font color="blue">products directly</font> or     through <font color="blue">distribution</font> alliances</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">introduce new <font color="blue">commercially</font> <font color="blue">successful product</font>s</font> in a timely     manner, our <font color="blue">products may</font> become obsolete over time, <font color="blue">thereby decreasing</font> our     revenue and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Demand for our <font color="blue">products may</font> change because of evolving customer needs,     the <font color="blue">introduction</font> of <font color="blue">new products</font> and <font color="blue">technologies</font>, the <font color="blue">discovery</font> of cures     for certain medical problems, evolving surgical practices and evolving     industry standards</td>
    </tr>
    <tr>
      <td>Without the timely <font color="blue">introduction</font> of new <font color="blue">commercially</font>     <font color="blue">successful product</font>s and <font color="blue">enhancements</font>, our <font color="blue">products may</font> become obsolete over     time, causing our sales and operating results to suffer</td>
    </tr>
    <tr>
      <td>The success of our     <font color="blue">new products</font> will depend on <font color="blue">several factors</font>, including our ability to:       •   properly identify and anticipate customer needs;         •   commercialize <font color="blue">new products</font> in a cost-effective and <font color="blue">timely manner</font>;         •   <font color="blue">manufacture</font> and deliver products in <font color="blue">sufficient volumes on</font> time;         •   obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for <font color="blue">new products</font>;         •   differentiate our <font color="blue">products from</font> those of our <font color="blue">competitors</font>;         _________________________________________________________________             •   achieve positive <font color="blue">clinical outcomes</font>;         •   satisfy the increased demands by health care payors, providers and     patients for lower-cost procedures and <font color="blue">shorter hospital stays</font> and recovery     times;         •   innovate and develop new materials, product designs and surgical     <font color="blue">techniques</font>; and         •   provide adequate medical and/or customer education relating to new     products and <font color="blue">attract key surgeons</font> to advocate these <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>New products and <font color="blue">enhancements</font> usually require a substantial <font color="blue">investment</font>     in research and <font color="blue">development</font> before we can determine the viability of the     product, and we may not have the <font color="blue">financial resources <font color="blue">necessary</font></font> to fund this     research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">new products</font> and <font color="blue">enhancements</font> may not     produce revenues in excess of the research and <font color="blue">development</font> costs, and they     <font color="blue">may become obsolete by</font> changing <font color="blue">customer preferences</font> or the <font color="blue">introduction</font> by     our <font color="blue">competitors</font> of new <font color="blue">technologies</font> or features</td>
    </tr>
    <tr>
      <td>Our operating results <font color="blue">may fluctuate</font></td>
    </tr>
    <tr>
      <td>Some of the factors that may     cause these <font color="blue">fluctuations</font> include, but are not limited to:       •   the <font color="blue">introduction</font> of <font color="blue">new product lines</font>;         •   <font color="blue">product modifications</font>;         •   the level of market <font color="blue">acceptance</font> of <font color="blue">new products</font>;         •   the timing of research and <font color="blue">development</font> <font color="blue">expenditures</font>;         •   timing of the receipt of <font color="blue">orders from</font>, and <font color="blue">product shipments</font> to,     <font color="blue">distributors</font> and customers;         •   timing of <font color="blue">expenditures</font>;         •   changes in the <font color="blue">distribution</font> arrangements for our products;         •   <font color="blue">manufacturing</font> or <font color="blue">supply delays</font>;         •   the time needed to educate and <font color="blue">train <font color="blue">additional</font> sales personnel</font>;         •   <font color="blue">costs associated with</font> product <font color="blue">introduction</font>s;         •   <font color="blue">product returns</font>; and         •   receipt of <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approval</font>s</td>
    </tr>
    <tr>
      <td>_________________________________________________________________           Changes in the <font color="blue">health care industry may</font> require us to decrease the selling     price for our products or could result in a reduction in the size of the     market for our products, each of <font color="blue">which could</font> have a <font color="blue">negative impact on</font> our     <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>Trends toward managed care, health care cost containment and other     changes in <font color="blue">government</font> and private sector <font color="blue">initiatives</font> in the <font color="blue">United States </font>    and other countries in which we do business are <font color="blue">placing increased emphasis</font>     on  the  delivery  of more cost-effective medical therapies that could     <font color="blue"><font color="blue">adversely</font> affect</font> the sale or the prices of our products</td>
    </tr>
    <tr>
      <td>For example:       •   there has been a <font color="blue">consolidation among health care facilities</font> and     purchasers of <font color="blue">medical devices</font> in the <font color="blue">United States </font>who prefer to limit the     number of suppliers from whom they purchase <font color="blue">medical products</font> and these     entities may decide to stop purchasing their products or demand <font color="blue">discounts</font> on     our prices;         •   major third-party payors of hospital services, including Medicare,     Medicaid and private health care insurers could <font color="blue">substantially</font> revise their     payment <font color="blue">methodologies</font> or could impose <font color="blue">reimbursement</font> cutbacks that could     create downward price pressure on our products;         •   numerous <font color="blue">legislative</font> proposals have been considered that would result     in major reforms in the <font color="blue">United States </font><font color="blue">health care system</font> that could have an     adverse effect on our business;          •     there  is  economic  pressure to <font color="blue">contain health care costs</font> in     <font color="blue">international markets</font>; and         •   there have been <font color="blue">initiatives</font> by third-party payors to challenge the     <font color="blue">prices charged</font> for <font color="blue">medical products</font> that <font color="blue">could affect</font> our ability to sell     <font color="blue">products on</font> a <font color="blue"><font color="blue">competitive</font> basis</font></td>
    </tr>
    <tr>
      <td>Both the pressures to reduce prices for our products in response to these     trends and the decrease in the size of the <font color="blue">market as</font> a result of these     trends could <font color="blue"><font color="blue">adversely</font> affect</font> our levels of revenues and <font color="blue">profitability</font> of     our sales</td>
    </tr>
    <tr>
      <td>We will first need to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> to market our products     under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our  research  and  <font color="blue">development</font> activities and the <font color="blue">manufacturing</font>,     labeling, <font color="blue">distribution</font> and marketing of our existing and <font color="blue">future products</font> are     subject to regulation by <font color="blue">government</font>al agencies in the <font color="blue">United States </font>and in     other countries</td>
    </tr>
    <tr>
      <td>The FDA and comparable agencies in other <font color="blue">countries impose</font>     <font color="blue">mandatory procedures</font> and standards for the conduct of <font color="blue">clinical trials</font> and     the  production  and  marketing  of  products for <font color="blue">diagnostic</font> and human     <font color="blue">therapeutic use</font></td>
    </tr>
    <tr>
      <td>Products we have under <font color="blue">development</font> are subject to FDA approval or     clearance before marketing for <font color="blue">commercial use</font></td>
    </tr>
    <tr>
      <td>The process of obtaining     <font color="blue">necessary</font> FDA approvals or <font color="blue">clearances</font> can take years and is expensive and     full of <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to obtain required <font color="blue"><font color="blue">regulatory</font> approval</font>     or  <font color="blue">clearance on</font> a timely or acceptable <font color="blue">basis could harm</font> our business</td>
    </tr>
    <tr>
      <td>Further, approval or <font color="blue">clearance may</font> place substantial <font color="blue">restrictions on</font> the     <font color="blue">indications</font> for which the <font color="blue">product may</font> be marketed or to whom it may be     marketed</td>
    </tr>
    <tr>
      <td>Further <font color="blue">studies may</font> be required to <font color="blue">gain approval</font> or clearance for     the use of a product for clinical <font color="blue">indications</font> other than those for which the     product was <font color="blue">initially approved</font> or cleared or for <font color="blue">significant</font> changes to the     product</td>
    </tr>
    <tr>
      <td>Furthermore, another risk of <font color="blue">application</font> to the FDA relates to the     <font color="blue">regulatory</font> classification of <font color="blue">new products</font> or <font color="blue">proposed new uses</font> for existing     products</td>
    </tr>
    <tr>
      <td>In the filing of each <font color="blue">application</font>, we are required to make a     judgment about the <font color="blue">appropriate</font> form and content of the <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>If the     FDA <font color="blue">disagrees with</font> our judgment in any <font color="blue">particular case</font> and, for example,     requires us to file a PMA <font color="blue">rather than allowing us</font> to market for approved     uses  while we <font color="blue">seek broader approvals</font> or requires extensive <font color="blue">additional</font>     <font color="blue">clinical data</font>, the time and expense required to obtain the <font color="blue">approval might</font> be     <font color="blue">significant</font>ly increased or <font color="blue">approval might</font> not be granted</td>
    </tr>
    <tr>
      <td>Approved and     cleared products are subject to         _________________________________________________________________           continuing  FDA  <font color="blue">requirements</font>  relating to quality control and quality     assurance, maintenance of records, reporting of <font color="blue">adverse events</font> and product     recalls, documentation and labeling and promotion of <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>We may be subject to penalties and may be <font color="blue">precluded from marketing</font> our     products if we fail to <font color="blue">comply with</font> extensive <font color="blue">government</font>al regulations</td>
    </tr>
    <tr>
      <td>The FDA and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> require that our products be     <font color="blue">manufacture</font>d <font color="blue">according</font> to rigorous standards</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulatory</font> <font color="blue">requirements</font>     may <font color="blue">significant</font>ly increase our <font color="blue">production costs</font> and <font color="blue">may even prevent us from</font>     making our products in <font color="blue">amounts sufficient</font> to <font color="blue">meet market demand</font></td>
    </tr>
    <tr>
      <td>If we     change our approved <font color="blue">manufacturing</font> process, the FDA may need to review the     process  before  it  may be used</td>
    </tr>
    <tr>
      <td>Failure to develop our <font color="blue">manufacturing</font>     <font color="blue">capability</font> may mean that even if we develop promising <font color="blue">new products</font>, we may     not  be  able to produce them <font color="blue">profitability</font>, as a result of delays and     <font color="blue">additional</font> capital <font color="blue">investment</font> costs</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> applicable     <font color="blue">regulatory</font> <font color="blue">requirements</font> discussed <font color="blue">throughout</font> this Form 10-K could subject us     to <font color="blue">enforcement actions</font>, including:       •   <font color="blue">warning letters</font>;         •   fines, injunctions and <font color="blue">civil penalties against us</font>;         •   recall or seizure of our products;         •   operating restrictions, partial suspension or <font color="blue">total shutdown</font> of our     production;         •   refusing our requests for <font color="blue">premarket clearance</font> or approval of new     products;         •   <font color="blue">withdrawing product approvals already granted</font>; and         •   <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>The various <font color="blue">regulatory</font> schemes that govern the use of our products in     the  <font color="blue">international market may</font> change, and we may be required to obtain     <font color="blue">additional</font> marketing clearance for our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">complexity</font>, timeframes     and <font color="blue">costs associated with</font> obtaining marketing <font color="blue">clearances</font> are unknown</td>
    </tr>
    <tr>
      <td>We  will first need to obtain <font color="blue">electrical safety approval</font> to market our     applicable products under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The majority of our <font color="blue">capital equipment products also</font> require electrical     <font color="blue">safety testing</font>, and in some cases, electromagnetic compatibility testing, as     either a <font color="blue">product registration</font> or to gain market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>The electrical     <font color="blue">safety testing</font> and electromagnetic compatibility testing <font color="blue">requirements</font> may     change and require us to redesign and retest our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">complexity</font>,     timeframes and <font color="blue">costs associated with</font> potential redesign and retesting are     unknown</td>
    </tr>
    <tr>
      <td>Our <font color="blue">intellectual</font> property rights may not <font color="blue">provide meaningful commercial</font>     protection  for our products and could <font color="blue"><font color="blue">adversely</font> affect</font> our ability to     compete in the market</td>
    </tr>
    <tr>
      <td>Our ability to compete <font color="blue">effectively</font> depends, in part, on our ability to     maintain  the <font color="blue">proprietary</font> nature of our <font color="blue">technologies</font> and <font color="blue">manufacturing</font>     processes, which includes the ability to obtain, protect and <font color="blue">enforce patents</font>     on our <font color="blue">technology</font> and to protect our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>We own patents that     cover <font color="blue">significant</font> aspects of our products</td>
    </tr>
    <tr>
      <td>In addition, challenges may be     made  to  our patents and, as a result, our <font color="blue">patents could</font> be narrowed,     invalidated or rendered unenforceable</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may develop products     similar to ours that our patents do not cover</td>
    </tr>
    <tr>
      <td>In addition, our current and     future patent <font color="blue"><font color="blue">application</font>s</font> may not result in the issuance of patents in the     <font color="blue">United States </font>or foreign countries</td>
    </tr>
    <tr>
      <td>Further, there is a substantial backlog     of         _________________________________________________________________           patent  <font color="blue"><font color="blue">application</font>s</font>  in the US Patent and Trademark Office, and the     approval or rejection of patent <font color="blue"><font color="blue">application</font>s</font> may take <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>We may     become subject to <font color="blue">patent <font color="blue">infringement</font></font> claims or <font color="blue">litigation</font> or <font color="blue">interference</font>     <font color="blue">proceedings</font> declared by the <font color="blue">US Patent and Trademark Office </font>to determine     the priority of invention</td>
    </tr>
    <tr>
      <td>Our  <font color="blue"><font color="blue">competitive</font> position depends</font>, in part, <font color="blue">upon unpatented trade</font>     secrets, which can be <font color="blue">difficult</font> to protect</td>
    </tr>
    <tr>
      <td>Others may in<font color="blue">dependent</font>ly develop     <font color="blue">substantially</font> equivalent <font color="blue">proprietary</font> information and <font color="blue">techniques</font> or otherwise     <font color="blue">gain access</font> to our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>In an effort to protect our <font color="blue">trade secrets</font>,     we  require  all of our employees, <font color="blue">consultants</font> and advisors to execute     <font color="blue">proprietary</font> information <font color="blue">agreements</font> and certain of them to sign invention     <font color="blue">assignment</font>  <font color="blue">agreements</font>  upon  <font color="blue">commencement</font> of <font color="blue">employment</font> or consulting     <font color="blue">relationships</font> with us</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreements</font> typically provide that, except in     <font color="blue">specified circumstances</font>, all <font color="blue">confidential</font> information developed or made     known to the individual during the course of his or her <font color="blue">relationship with us</font>     must be kept <font color="blue">confidential</font></td>
    </tr>
    <tr>
      <td>They <font color="blue">also contain provisions</font> requiring these     <font color="blue">individuals</font>  to  assign  to  us, without <font color="blue">additional</font> consideration, any     <font color="blue">inventions</font>  conceived or reduced to <font color="blue">practice by them while employed</font> or     retained by us, subject to <font color="blue">customary exceptions</font></td>
    </tr>
    <tr>
      <td>Some <font color="blue">jurisdictions limit</font>     the <font color="blue">enforceability</font> and scope of these <font color="blue">agreements</font> and these <font color="blue">agreements</font> may     not <font color="blue">provide meaningful protection</font> for our <font color="blue">trade secrets</font> or other <font color="blue">proprietary</font>     information  in  the  event  of  the <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font> of     <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>The medical device industry is <font color="blue">characterized</font> by frequent <font color="blue">litigation</font>     regarding patent and other <font color="blue">intellectual</font> property rights</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>in the     medical device industry have employed <font color="blue">intellectual</font> property <font color="blue">litigation</font> to     gain a <font color="blue"><font color="blue">competitive</font> advantage</font></td>
    </tr>
    <tr>
      <td>Numerous patents are held by others, including     academic  <font color="blue">institutions</font>  and  our  <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Until  <font color="blue">recently patent</font>     <font color="blue"><font color="blue">application</font>s</font> were maintained in secrecy in the <font color="blue">United States </font>until after the     patent had <font color="blue">been issued</font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue"><font color="blue">application</font>s</font>, filed in the <font color="blue">United States </font>    after November 2000 generally will be published 18 months after the filing     date</td>
    </tr>
    <tr>
      <td>However, since patent <font color="blue"><font color="blue">application</font>s</font> continue to be maintained in     secrecy for at least some period of time, we <font color="blue">cannot assure</font> you that our     <font color="blue">technology</font> does not infringe any patents, patent <font color="blue"><font color="blue">application</font>s</font> held by third     parties or <font color="blue">prior patents</font></td>
    </tr>
    <tr>
      <td>We have, from time to time, <font color="blue">been notified</font> of, or     have  otherwise been made aware of, claims that we are <font color="blue">infringing upon</font>     patents or other <font color="blue">proprietary</font> <font color="blue">intellectual</font> property owned by others</td>
    </tr>
    <tr>
      <td>If it     appears <font color="blue">necessary</font> or desirable, we <font color="blue">may seek licenses under such patents</font> or     <font color="blue">proprietary</font> <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>Although <font color="blue">patent holders may offer such</font>     licenses, licenses under such patents or <font color="blue">intellectual</font> property may not be     offered or the terms of any <font color="blue">offered licenses may</font> not be reasonable</td>
    </tr>
    <tr>
      <td>Any claims, with or <font color="blue">without merit</font>, and <font color="blue">regardless</font> of whether we are     successful  on  the  merits, would be time-consuming, result in costly     <font color="blue">litigation</font>  and diversion of technical and <font color="blue"><font color="blue">management</font> personnel</font>, cause     <font color="blue">shipment delays</font> or require us to develop non-infringing <font color="blue">technology</font> or enter     <font color="blue">into royalty</font> or licensing <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>An adverse determination could prevent     us from <font color="blue">manufacturing</font> or selling our products, which would have a material     adverse  effect  on  our business, results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>In  October 2005,  IRIDEX  <font color="blue">filed suit against</font> <font color="blue">Synergetics USA </font>for     <font color="blue">infringement</font> of a patent</td>
    </tr>
    <tr>
      <td>IRIDEX <font color="blue">seeks damages</font>, including <font color="blue">treble damages</font> and     <font color="blue">injunctive relief</font></td>
    </tr>
    <tr>
      <td>In addition, we     <font color="blue">countersued</font> IRIDEX alleging that it engaged in false advertising, commercial     disparagement, trade libel, injurious falsehood and unfair <font color="blue">competition</font> under     the <font color="blue">Federal Lanham Act </font>and applicable Missouri law</td>
    </tr>
    <tr>
      <td>While we believe that we     have  substantial  <font color="blue">meritorious</font>  defenses to their claims, we may incur     <font color="blue">significant</font> dedication of <font color="blue"><font color="blue">management</font> resources</font> and <font color="blue">legal costs</font> in <font color="blue">connection</font>     with this lawsuit</td>
    </tr>
    <tr>
      <td>We may have <font color="blue">product <font color="blue">liability</font></font> claims, and our <font color="blue">insurance may</font> not cover all     claims</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font>, <font color="blue">manufacture</font>, sale and use of <font color="blue">medical products</font> entail     <font color="blue">significant</font> risk of <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>We maintain <font color="blue">product <font color="blue">liability</font></font>     <font color="blue">coverage at levels</font> we have determined are reasonable</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that <font color="blue">such coverage limits</font> are adequate to <font color="blue">protect us from</font> any <font color="blue">liabilities</font> we     <font color="blue">might incur</font> in <font color="blue">connection</font> with the <font color="blue">development</font>, <font color="blue">manufacture</font>, sale or use of     our products</td>
    </tr>
    <tr>
      <td>In addition, we may require increased <font color="blue">product <font color="blue">liability</font></font>         _________________________________________________________________           coverage  as  our <font color="blue">sales increase</font> in their current <font color="blue"><font color="blue">application</font>s</font> and new     <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue"><font color="blue">liability</font> insurance</font> is expensive and in the <font color="blue">future may</font>     not  be <font color="blue">available on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>A <font color="blue">successful product</font>     <font color="blue">liability</font> claim or series of claims <font color="blue">brought against us</font> in excess of our     insurance coverage could <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>The loss of <font color="blue"><font color="blue">key personnel</font> could harm</font> our business</td>
    </tr>
    <tr>
      <td>We believe our <font color="blue">success depends on</font> the <font color="blue">contributions</font> of a number of our     <font color="blue">key personnel</font>, including Messrs</td>
    </tr>
    <tr>
      <td>Boone,     our Chief Executive Officer, Chief Operating Officer, Chief Scientific     Officer and Chief Financial Officer, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>If we lose the services     of  <font color="blue">key personnel</font>, those <font color="blue">losses could materially harm</font> our business</td>
    </tr>
    <tr>
      <td>We     maintain key person <font color="blue">life insurance</font> of Messrs</td>
    </tr>
    <tr>
      <td>If we are unable to hire, train and retain <font color="blue">additional</font> sales, marketing,     <font color="blue">manufacturing</font>,  <font color="blue">engineering</font> and <font color="blue">finance personnel</font>, our <font color="blue">growth could</font> be     impaired</td>
    </tr>
    <tr>
      <td>To grow our business <font color="blue">successfully</font> and maintain a <font color="blue">high level</font> of quality,     we  will  need  to  recruit, retain and motivate highly-skilled sales,     marketing, <font color="blue">engineering</font>, <font color="blue">manufacturing</font> and <font color="blue">finance personnel</font></td>
    </tr>
    <tr>
      <td>If we are not     able to hire, train, and retain a sufficient number of <font color="blue">qualified employees</font>,     our <font color="blue">growth may</font> be impaired</td>
    </tr>
    <tr>
      <td>In particular, we will need to expand our sales     and <font color="blue">marketing organizations</font> in order to <font color="blue">increase market awareness</font> of our     products and to <font color="blue">increase revenues</font></td>
    </tr>
    <tr>
      <td>In addition, as a <font color="blue">company focused on</font> the     <font color="blue">development</font> of <font color="blue">complex products</font>, we will need to hire <font color="blue">additional</font> <font color="blue">engineering</font>     staff of various experience levels in order to meet our product <font color="blue">development</font>     strategy</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for skilled employees is intense</td>
    </tr>
    <tr>
      <td>We plan to expand our <font color="blue">international sales</font> and <font color="blue">distribution</font> <font color="blue">operations</font>, and     the  success  of our <font color="blue">international expansion</font> is subject to <font color="blue">significant</font>     <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>We believe that we must expand our <font color="blue">international sales</font> and <font color="blue">distribution</font>     <font color="blue">operations</font> to have <font color="blue">continued growth</font></td>
    </tr>
    <tr>
      <td>We expect to sell an increasing portion     of our products to <font color="blue">customers overseas</font></td>
    </tr>
    <tr>
      <td>In attempting to conduct and expand     business  <font color="blue">internationally</font>,  we are exposed to <font color="blue">various risks</font> that could     <font color="blue">adversely</font>  affect  our international <font color="blue">operations</font> and, <font color="blue">consequently</font>, our     operating results, including:       •   <font color="blue">difficult</font>ies and costs of staffing and <font color="blue">managing international</font>     <font color="blue">operations</font>;         •   <font color="blue">fluctuations</font> in <font color="blue">currency exchange rates</font>;         •   unexpected changes in <font color="blue">regulatory</font> <font color="blue">requirements</font>, including imposition of     <font color="blue">currency exchange controls</font>;         •   <font color="blue">longer accounts receivable collection cycles</font>;         •   import or export licensing <font color="blue">requirements</font>;         •   <font color="blue">potentially adverse tax consequences</font>;         •   political and <font color="blue">economic instability</font>;         •   obtaining <font color="blue"><font color="blue">regulatory</font> approval</font> for our products;         •   end-market and/or regional <font color="blue">competition</font> that may have <font color="blue">competitive</font>     <font color="blue">advantages</font>;         •   <font color="blue">potentially reduced protection</font> for <font color="blue">intellectual</font> property rights; and         _________________________________________________________________             •   <font color="blue">subjectivity</font> of <font color="blue">foreign laws</font></td>
    </tr>
    <tr>
      <td>In addition, because we have suppliers that are <font color="blue">located outside</font> the     United States, we are subject to <font color="blue">risks generally associated with contracting</font>     <font color="blue">with foreign suppliers</font> and may experience problems in the <font color="blue">timeliness</font> and the     adequacy or quality of <font color="blue">product deliveries</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our stock may be <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> could fluctuate <font color="blue">substantially</font> due     to a variety of factors, including:       •   our ability to <font color="blue">successfully</font> commercialize our products;         •   the execution of new <font color="blue">agreements</font> and material changes in our     <font color="blue">relationships</font> with companies with whom we contract;         •   quarterly <font color="blue">fluctuations</font> in results of <font color="blue">operations</font>;         •   <font color="blue">announcements</font> regarding <font color="blue">technological innovations</font> or <font color="blue">new commercial</font>     <font color="blue">products by us</font> or our <font color="blue">competitors</font> or the results of <font color="blue">regulatory</font> filings;          •    <font color="blue">market reaction</font> to trends in sales, marketing and research and     <font color="blue">development</font> and reaction to <font color="blue"><font color="blue">acquisition</font>s</font>;         •   sales of <font color="blue"><font color="blue">common stock</font> by existing <font color="blue">shareholders</font></font>;         •   economic and <font color="blue">political condition</font>, including <font color="blue">worldwide geopolitical</font>     events; and         •   <font color="blue">fluctuations</font> in the <font color="blue">United States </font><font color="blue">financial markets</font></td>
    </tr>
    <tr>
      <td><font color="blue">Synergetics USA </font>has anti-takeover defenses that <font color="blue">could delay</font> or prevent an     <font color="blue">acquisition</font> and could <font color="blue"><font color="blue">adversely</font> affect</font> the price of its <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our <font color="blue">certificate</font> of incorporation, bylaws <font color="blue">and Delaware </font>law     may have the effect of <font color="blue">deterring hostile takeovers</font> or delaying or preventing     changes in the control of our <font color="blue">management</font>, including <font color="blue">transactions</font> in which     our <font color="blue"><font color="blue">shareholders</font> might otherwise</font> receive a premium for their <font color="blue">shares over</font>     then current <font color="blue">market price</font>s</td>
    </tr>
    <tr>
      <td>In addition, these <font color="blue">provisions may limit</font> the     ability of our <font color="blue">shareholders</font> to approve <font color="blue">transactions</font> that they may deem to be     in their <font color="blue">best interest</font></td>
    </tr>
    <tr>
      <td>Also, our board of <font color="blue">directors</font> is <font color="blue">divided into three</font>     classes, as nearly equal in size as practicable, with three-year staggered     terms</td>
    </tr>
    <tr>
      <td>This <font color="blue">provision may deter</font> a <font color="blue">potential acquirer from</font> engaging in a     <font color="blue">transaction with us</font> because it will be unable to <font color="blue">gain control</font> of our board     of <font color="blue">directors</font> until at least two annual meetings in which <font color="blue">directors</font> are     <font color="blue">elected by</font> our <font color="blue">shareholders</font></td>
    </tr>
  </tbody>
</table>